Relay Therapeutics reported second-quarter earnings per share of $(0.41), missing the analyst consensus estimate of $(0.39) by 5.13 percent. The company’s quarterly sales came in at $350.000 thousand, falling short of the $872.727 thousand estimate by 59.90 percent. This revenue figure represents a 48.30 percent decrease compared to sales of $677.000 thousand recorded in the same period last year. The widening gap between actual performance and analyst expectations highlights execution challenges in the current quarter.

The earnings miss was relatively narrow in absolute terms but signals continued pressure on profitability metrics relative to market forecasts. While the loss per share remained unchanged from the same period last year, the significant contraction in top-line growth underscores operational headwinds. Analysts had anticipated stronger commercial traction, as evidenced by the substantial variance between the estimated and actual sales figures.

Financial Performance Overview

The following table details the key financial metrics for the quarter compared to analyst estimates and year-over-year figures:

Revenue declined sharply from $677.000 thousand in the prior year period to $350.000 thousand this quarter. This near-halving of sales volume indicates a material slowdown in business activity or product uptake during the reporting window.

What the Numbers Show

The divergence between the modest miss on earnings per share and the severe miss on sales suggests that cost structures or other income items may have partially offset the revenue shortfall. However, with sales missing estimates by nearly 60 percent, the primary driver of investor concern remains the inability to meet top-line projections. The fact that losses per share were unchanged year-over-year despite a 48.30 percent drop in sales implies that operating expenses did not scale down proportionally with revenue, potentially pressuring margins further than the headline EPS figure indicates.

Relay Therapeutics, Inc. (NASDAQ: RLAY) will report second quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Thursday, August 6, 2026. The announcement provides investors with an update on the clinical-stage company’s financial position and progress in developing precision medicine therapies for patients living with cancer and genetic disease.

The disclosure follows standard reporting timelines for publicly traded biotechnology firms. Relay Therapeutics operates as a small molecule precision medicine company, utilizing its Dynamo platform to target protein targets that have previously been intractable or inadequately addressed.

Pipeline Progress

The company’s lead clinical asset, zovegalisib, remains a central focus of its development efforts. Zovegalisib is the first pan-mutant selective PI3Kα inhibitor to enter clinical development. It is currently in a Phase 3 clinical trial, known as ReDiscover-2, for HR+/HER2- metastatic breast cancer.

In addition to oncology indications, zovegalisib is being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. The broader pipeline also includes programs targeting NRAS-driven solid tumors and Fabry disease.

Key Developments

What This Means for Investors

For shareholders, the upcoming earnings release serves as a critical checkpoint for assessing the capital requirements and operational efficiency of Relay Therapeutics. As a clinical-stage entity, the company’s value is heavily tied to the successful progression of its late-stage assets like zovegalisib. Investors will likely scrutinize cash runway, burn rate, and any updates regarding the timeline for the ReDiscover-2 trial data readout or regulatory milestones.

The Dynamo platform’s ability to drug previously intractable targets underpins the company’s long-term growth thesis. Success in expanding the label for zovegalisib beyond breast cancer into genetic diseases could significantly enhance the asset’s commercial potential.

Contact Information

Investors and media seeking further details can contact Mitch Maisel at mmaisel@relaytx.com . Media inquiries are handled by Katie Engleman at 1AB, reachable at 919-333-7722 or katie@1abmedia.com .